Patient-reported Outcomes in Neuroendocrine Neoplasms: a Prospective Quality of Life and Quality of Care Study Within NETwerk

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Neuroendocrine tumors (NET) are rare tumors that require specific diagnosis and treatment. Therefore, this poses a challenge for clinical practice. Diagnosis and treatment can be optimized when physician specialists and other healthcare providers, across various hospitals, join forces to provide patients the best care. Based on this idea, a hospital network called NETwerk was set up. The following hospitals are part of this network: University Hospital Antwerp, VITAZ, AZ Monica, AZ Voorkempen, AZ Klina, Gasthuiszusters Antwerpen, Ziekenhuis Netwerk Antwerpen and AZ Rivierenland. In this NETwerk, patients with a neuroendocrine tumor or patients suspected with a neuroendocrine tumor are discussed with the specialists and treated.The aim of this study is to map the quality of life of NET patients within NETwerk in order to optimize the quality of care. Throughout the diagnosis, the treatment process and the follow-up, the patient will be asked to fill out three questionnaires (QLQ-C30, QLQ-GI.NET21 and a satisfaction survey). These questionnaires will be filled out every six months at home. Patients will be asked to complete these questionnaires over a period of five years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• NEN patient

• 18 years or older

• Patient should appear in Oncobase

Locations
Other Locations
Belgium
GZA
RECRUITING
Antwerp
ZNA
RECRUITING
Antwerp
AZ Klina
RECRUITING
Brasschaat
AZ Monica
NOT_YET_RECRUITING
Deurne
Antwerp University Hospital
RECRUITING
Edegem
AZ Rivierenland
RECRUITING
Rumst
VITAZ
RECRUITING
Sint-niklaas
Contact Information
Primary
Timon U Vandamme
timon.vandamme@uza.be
03821
Backup
Isolde Van der Massen
Time Frame
Start Date: 2018-11-05
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 1000
Treatments
Experimental: NEN patients
EORTC QLQ-C30, EORTC QLQ-GI.NET21 and satisfaction survey
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Antwerp

This content was sourced from clinicaltrials.gov